ATE198891T1 - Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems - Google Patents

Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems

Info

Publication number
ATE198891T1
ATE198891T1 AT93304102T AT93304102T ATE198891T1 AT E198891 T1 ATE198891 T1 AT E198891T1 AT 93304102 T AT93304102 T AT 93304102T AT 93304102 T AT93304102 T AT 93304102T AT E198891 T1 ATE198891 T1 AT E198891T1
Authority
AT
Austria
Prior art keywords
treatment
nervous system
central nervous
system disorders
alkyl
Prior art date
Application number
AT93304102T
Other languages
German (de)
English (en)
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE198891T1 publication Critical patent/ATE198891T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93304102T 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems ATE198891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE198891T1 true ATE198891T1 (de) 2001-02-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93304102T ATE198891T1 (de) 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems

Country Status (21)

Country Link
EP (1) EP0582368B1 (Direct)
JP (1) JP3219541B2 (Direct)
CN (1) CN1043994C (Direct)
AT (1) ATE198891T1 (Direct)
AU (1) AU668159B2 (Direct)
CA (1) CA2097016A1 (Direct)
CZ (1) CZ282783B6 (Direct)
DE (1) DE69329887T2 (Direct)
DK (1) DK0582368T3 (Direct)
ES (1) ES2153373T3 (Direct)
FI (1) FI101538B (Direct)
GR (1) GR3035587T3 (Direct)
HU (1) HU218278B (Direct)
IL (1) IL105827A (Direct)
MX (1) MX9303124A (Direct)
MY (1) MY109943A (Direct)
NO (1) NO305125B1 (Direct)
NZ (1) NZ247703A (Direct)
PT (1) PT582368E (Direct)
RU (1) RU2125574C1 (Direct)
TW (1) TW268005B (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CN1219878A (zh) * 1996-03-25 1999-06-16 伊莱利利公司 治疗疼痛的方法
CZ298398A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
EP0921802A4 (en) * 1996-03-25 2002-05-08 Lilly Co Eli METHODS FOR TREATING PAIN
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
PL332503A1 (en) * 1996-09-24 1999-09-13 Lilly Co Eli Coated particles containing preparation
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
EP3663317B1 (en) 2012-08-21 2022-10-12 Janssen Pharmaceutica NV Antibodies to quetiapine haptens and use thereof
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
WO2014031601A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of risperidone and paliperidone
AU2013305935B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of quetiapine for use in immunoassays
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
EP3556759B1 (en) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptens of paliperidone
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
EP3581195B1 (en) 2012-08-21 2025-10-01 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (Direct) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
CH624682A5 (Direct) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
FI932445L (fi) 1993-11-30
DE69329887T2 (de) 2001-05-23
HU218278B (en) 2000-07-28
NO931917L (no) 1993-11-30
JP3219541B2 (ja) 2001-10-15
ES2153373T3 (es) 2001-03-01
CN1085903A (zh) 1994-04-27
CZ102493A3 (en) 1993-12-15
FI101538B1 (fi) 1998-07-15
IL105827A (en) 1997-02-18
DE69329887D1 (de) 2001-03-01
PT582368E (pt) 2001-05-31
DK0582368T3 (da) 2001-02-05
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
HU9301579D0 (en) 1993-09-28
IL105827A0 (en) 1993-09-22
MY109943A (en) 1997-10-31
FI101538B (fi) 1998-07-15
CA2097016A1 (en) 1993-11-30
NO931917D0 (no) 1993-05-26
CZ282783B6 (cs) 1997-10-15
CN1043994C (zh) 1999-07-07
NZ247703A (en) 1995-07-26
AU3980793A (en) 1993-12-02
JPH0687862A (ja) 1994-03-29
NO305125B1 (no) 1999-04-06
FI932445A0 (fi) 1993-05-28
GR3035587T3 (en) 2001-06-29
TW268005B (Direct) 1996-01-11
RU2125574C1 (ru) 1999-01-27
MX9303124A (es) 1993-11-01
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26

Similar Documents

Publication Publication Date Title
DE69329887D1 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
IE893246L (en) Biologically active compounds
ES2164718T3 (es) Compuestos triciclicos de amida y urea utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
MX9200015A (es) Derivados de amida y proceso para su preparacion.
DE69411424D1 (de) Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
NO1998008I1 (no) Naratriptan
FI893751A0 (fi) Kemiska foereningar.
ATE88894T1 (de) Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen.
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
MA21902A1 (fr) Procede pour la preparation de peptitides hemoregulateurs et des compositions pharmaceutiques les comtenant .
ATE69049T1 (de) Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ES2097188T3 (es) Derivados organosilanos, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee